PMID- 35428573
OWN - NLM
STAT- MEDLINE
DCOM- 20220512
LR  - 20220512
IS  - 1437-7780 (Electronic)
IS  - 1341-321X (Linking)
VI  - 28
IP  - 7
DP  - 2022 Jul
TI  - Performance of the new FilmArray Blood Culture Identification 2 panel and its 
      potential impact on clinical use in patients with Gram-negative bacteremia.
PG  - 1037-1040
LID - S1341-321X(22)00117-9 [pii]
LID - 10.1016/j.jiac.2022.04.008 [doi]
AB  - INTRODUCTION: Rapid diagnostic tests have been developed recently for rapid 
      species or resistance genes identification, offering the potential to improve the 
      selection of appropriate antibiotics. The newly developed FilmArray Blood Culture 
      Identification 2 (BCID2) panel, which can identify more species and resistance 
      genes, such as extended-spectrum beta-lactamase, is expected to make an impact on 
      antimicrobial practice. METHODS: The consecutive 50 inpatients with Gram-negative 
      bacilli bacteremia were enrolled to this retrospective single-center study. In 
      addition to the existing FilmArray Blood Culture Identification (BCID) panel, we 
      have implemented BCID2 panel for positive blood culture. The sensitivity and 
      specificity of BCID and BCID2 panel were respectively calculated, and a 
      simulation study of time to effective, optimal and de-escalation therapy was 
      performed based on BCID or BCID2 result. RESULTS: A total of 52 Gram-negative 
      organisms in 50 patients were identified from blood cultures. Of these, 45 (87%) 
      organisms were detected by BCID2 panel, which was more than BCID panel (41 
      organisms, 79%). BCID2 panel detected 5 CTX-M genes, which were concordant with 
      conventional method. The time to effective therapy did not differ between BCID 
      arm and BCID2 arm; however, the median time to optimal therapy (34 h in BCID arm 
      and 26 h in BCID2 arm, P = 0.0007) and the median time to de-escalation therapy 
      (42 h in BCID arm and 22 h in BCID2 arm, P = 0.0005) were significantly 
      shortened. CONCLUSIONS: This simulation study of BCID2 panel showed high 
      sensitivity and specificity, and the potential impact on shortening the time to 
      optimal and de-escalation therapy.
CI  - Copyright (c) 2022 Japanese Society of Chemotherapy and The Japanese Association 
      for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
FAU - Kanda, Naoki
AU  - Kanda N
AD  - Department of Emergency and Critical Care Medicine, Hitachi General Hospital, 
      Ibaraki, Japan; Division of General Internal Medicine, Jichi Medical University 
      Hospital, Tochigi, Japan.
FAU - Hashimoto, Hideki
AU  - Hashimoto H
AD  - Department of Emergency and Critical Care Medicine, Hitachi General Hospital, 
      Ibaraki, Japan; Department of Infectious Diseases, The University of Tokyo 
      Hospital, Tokyo, Japan. Electronic address: hidehashimoto-tky@umin.ac.jp.
FAU - Suzuki, Takahiro
AU  - Suzuki T
AD  - Department of Clinical Laboratory, Hitachi General Hospital, Ibaraki, Japan.
FAU - Nakamura, Kensuke
AU  - Nakamura K
AD  - Department of Emergency and Critical Care Medicine, Hitachi General Hospital, 
      Ibaraki, Japan.
LA  - eng
PT  - Journal Article
DEP - 20220412
PL  - Netherlands
TA  - J Infect Chemother
JT  - Journal of infection and chemotherapy : official journal of the Japan Society of 
      Chemotherapy
JID - 9608375
RN  - 0 (Anti-Bacterial Agents)
SB  - IM
MH  - Anti-Bacterial Agents/therapeutic use
MH  - *Bacteremia/diagnosis/drug therapy
MH  - *Blood Culture/methods
MH  - Gram-Positive Bacteria
MH  - Humans
MH  - Retrospective Studies
OTO - NOTNLM
OT  - Antimicrobial resistance
OT  - Antimicrobial stewardship
OT  - Extended-spectrum beta-lactamase
OT  - Nucleic acid amplification
OT  - Rapid diagnostic test
EDAT- 2022/04/17 06:00
MHDA- 2022/05/14 06:00
CRDT- 2022/04/16 05:19
PHST- 2022/01/16 00:00 [received]
PHST- 2022/03/29 00:00 [revised]
PHST- 2022/04/07 00:00 [accepted]
PHST- 2022/04/17 06:00 [pubmed]
PHST- 2022/05/14 06:00 [medline]
PHST- 2022/04/16 05:19 [entrez]
AID - S1341-321X(22)00117-9 [pii]
AID - 10.1016/j.jiac.2022.04.008 [doi]
PST - ppublish
SO  - J Infect Chemother. 2022 Jul;28(7):1037-1040. doi: 10.1016/j.jiac.2022.04.008. 
      Epub 2022 Apr 12.